119 results about "AIDS diagnosis" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for breast cancer diagnosis and application thereof. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the capture antibody is a monoclonal antibody T2X-1 of an anti-PSTPIP1 protein; the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an anti-PSTPIP1 protein, and the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an The heavy chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.4. The kit for breast cancer diagnosis provided by the invention can be used as an auxiliary diagnosis means for breast cancer with high expression of PSTPIP1 protein, and has high diagnostic value.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

This invention discloses an anti-HIV antibody or a functional fragment thereof and its applications. The anti-HIV antibody or functional fragment disclosed in this invention includes a heavy chain complementarity-determining region and a light chain complementarity-determining region. This antibody or functional fragment has good specificity and sensitivity for HIV and can be used to detect human immunodeficiency virus (HIV) and for the diagnosis or auxiliary diagnosis of related diseases using HIV as a biomarker.

The application relates to the field of disease prediction, and particularly relates to an epilepsy prediction system based on electroencephalogram-electrogastrogram signals collected synchronously, which comprises the following modules: a data acquisition module, which is used for acquiring data, wherein the data comprises electroencephalogram data and electrogastrogram data; a first analysis module, which is used for obtaining average electrode inconsistency indexes of first channels and second channels based on a first model according to time sequence data; and a prediction module, which is used for comparing the average electrode inconsistency indexes of a subject with preset evaluation thresholds, so as to predict epilepsy patients. The system provided by the application can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be applied to the preliminary screening of epilepsy for a large population (for example, a community or a physical examination center) as an auxiliary diagnosis tool.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The application discloses a cervical cancer methylation detection kit and application thereof, the kit takes PAX5 gene, PAX1 gene, MICOS10-NBL1 gene and MICOS10 gene as detection targets; the kit mainly comprises specific primer probe dry powder combination, PCR reaction reagent dry powder, positive control product dry powder, negative control product dry powder and microdroplet generation oil. The sample is detected by bisulfite conversion, and the kit is combined with microdroplet digital PCR detection technology to realize accurate detection of the methylation level of the target gene. The detection verification result shows that the sensitivity of the kit for cervical cancer detection reaches 96.9%, the specificity reaches 95.7%, the kit has the advantages of accurate detection, simple operation and strong stability, can be widely applied to early screening, clinical auxiliary diagnosis and physical examination of healthy people of cervical cancer, and provides reliable technical support for early discovery and early treatment of cervical cancer.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

This application provides a monoclonal antibody combination against NFL protein and its uses. The monoclonal antibody combination includes a first antibody and a second antibody. The first antibody includes a first heavy chain variable region and a first light chain variable region, and the second antibody includes a second heavy chain variable region and a second light chain variable region. The first heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:3-5, the first light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:6-8, the second heavy chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:11-13, and the second light chain variable region includes three complementarity-determining regions as shown in SEQ ID NO:14-16. The monoclonal antibody combination provided in this embodiment has excellent specificity and high affinity, and can be used for in vitro quantitative detection of serum NFL concentration, providing technical support for the auxiliary diagnosis of neurological diseases.

The application belongs to the technical field of biological medicine, and particularly discloses an application of insulin-like growth factors binding protein 6 (IGFBP6) as a biomarker in preparation of a sepsis diagnosis and treatment reagent. It is found by the application that IGFBP6 can be used as a new biological marker for assisting in diagnosis of sepsis, and can be used not only for diagnosis of diseases and reflecting severity of diseases, but also as a potential sepsis treatment target, so that a new technical means is provided for diagnosis, prognosis and treatment of sepsis diseases.

The application discloses a marker group for liver cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences SEQ ID NO.1-35.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of liver cancer, is superior to a GALAD model recommended by a current liver cancer clinical guideline and a detection kit based on seven miRNAs, and is also superior to AFP-L3% and PIVKA-II recommended by a current liver cancer early screening expert consensus, and is expected to be applied to the diagnosis and treatment of liver cancer.

The invention discloses a marker combination for diagnosing heart failure blood stasis syndrome and application thereof, the marker combination comprises a marker A and a marker B, the marker A is Cr, and the marker B is selected from at least one of PCSK9, AFM and APOC1. The marker combination provided by the invention is applied to clinical diagnosis or auxiliary diagnosis of heart failure blood stasis syndrome patients, has relatively high sensitivity and specificity, and can effectively distinguish the heart failure blood stasis syndrome patients from heart failure non-blood-stasis syndrome patients; reliable basis and practical guidance can be provided for clinical diagnosis and drug treatment of the heart failure blood stasis syndrome, and the accuracy and standardization degree of traditional Chinese medicine syndrome differentiation diagnosis can be improved.

The invention discloses a compound and a composition of a targeted folate receptor as well as a preparation method and application of the compound and the composition, and belongs to the technical field of medical biology, the compound of the targeted folate receptor is F-L-D, F is a structure of the targeted folate receptor, D is a near-infrared dye, L is a connexon, and the structural formula is shown in the specification or a pharmaceutically acceptable salt thereof. The compound of the targeted folate receptor is used as a targeted near-infrared fluorescence imaging agent, can be matched with a near-infrared fluorescence imaging system for use, can specifically target the folate receptor FR-alpha, and is used for auxiliary diagnosis of identifying malignant lesions in a tumor patient operation. In application scenarios of lung cancer and ovarian cancer, the compound can show higher TNR and can display tumor boundaries in real time so as to help to identify intraoperative lesions, reduce the positive edge cutting rate and the false positive rate and realize accurate excision.

This invention relates to the field of biomedical technology, specifically to the use of the N-terminal fragment of insulin-like growth factor binding protein-4 (IGF-4) in the clinical assessment of heart failure and coronary artery disease. The N-terminal fragment of IGF-4 is obtained by catalytic hydrolysis of IGF-4 by pregnancy-associated plasma protein A. Clinical assessment of heart failure includes diagnosing or assisting in the diagnosis of heart failure, or assessing or assisting in the prognostic risk of heart failure. Clinical assessment of coronary artery disease includes assessing or assisting in the prognostic risk of coronary artery disease. By detecting the content of the N-terminal fragment of IGF-4 in a sample, heart failure can be diagnosed or assisted in the diagnosis, and the prognosis of heart failure and coronary artery disease can be assessed or assisted in, demonstrating good clinical assessment efficacy.

The invention provides two new applications of taurochenodeoxycholic acid (TCDCA) in the field of alcohol related liver diseases (ALD), and belongs to the field of biological medicines. First, the invention proposes that TCDCA is used as a biomarker for auxiliary diagnosis and / or staging evaluation of ALD for the first time. Clinical research finds that the level of TCDCA in human serum is in significant positive correlation with the severity of ALD, and the TCDCA has extremely high accuracy in ALD diagnosis and can effectively assist in distinguishing different stages of diseases. Secondly, the invention discloses an application of TCDCA in preparation of a medicine for preventing and / or treating ALD (Atomic Lymphosis Disease). Researches show that the TCDCA can save ethanol-induced liver cell activity decline in a concentration-dependent manner and improve liver pathological indexes of mice. The TCDCA has double values of being used as an excellent biomarker and an effective prevention and treatment component, and a brand new strategy is provided for accurate diagnosis and prevention and treatment of ALD.

The present application belongs to the field of clinical medicine, and particularly relates to a method for establishing an esophageal cancer auxiliary diagnosis model based on immunoglobulin G Fc segment N-glycosyl in serum and application thereof. The biomarker on which the esophageal cancer auxiliary diagnosis model provided by the present application is based is immunoglobulin G Fc segment N-glycosyl GP10, GP11, GP14, GP17 and GP23. The diagnosis model provided by the present application is constructed based on the level of five initial immunoglobulin G N-glycosyl in serum, and has the advantages of simplicity, convenient calculation and easy judgment. The model has high accuracy, high sensitivity and strong specificity for esophageal cancer diagnosis, and is much higher than the diagnosis of the conventional cancer markers CEA and CA199. The esophageal cancer diagnosis model constructed by the present application provides an effective, reliable and convenient method for the clinical diagnosis of gastrointestinal health, and has good auxiliary diagnosis value for gastrointestinal health.

This invention discloses miRNA biomarkers for the auxiliary diagnosis of tuberculosis and their applications. This invention claims protection for the use of substances for detecting miRNAs in serum exosomes in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of tuberculosis patients or for the diagnosis or auxiliary diagnosis of active pulmonary tuberculosis patients. The miRNAs are any one or any combination of the following five miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246, and miR-2110. This invention also claims protection for the use of substances for detecting serum exosome miRNAs in the preparation of products; the purpose of said products is for the diagnosis or auxiliary diagnosis of latent tuberculosis infection. The miRNAs are any one or any combination of the following three miRNAs: let-7e-5p, let-7d-5p, and miR-140-5p. This invention lays the foundation for further development of rapid early diagnosis techniques and methods for tuberculosis.

Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

The invention provides a detection reagent for LXOL2 gene expression quantity and application of LXOL2 as a rheumatoid arthritis treatment target, and relates to the technical field of biological medicines. According to an extracted total RNA sequence, a specific PCR primer is designed and synthesized, an RT-qPCR technology and a sequencing method are utilized, the expression of the LXOL2 in human synovial fibroblast-like cells is found to be remarkably increased, it is proved that the LXOL2 can be applied to preparation of a preparation for auxiliary diagnosis, treatment or prognosis evaluation of rheumatoid arthritis, meanwhile, Si-LOXL2 small in interference with the gene is designed and synthesized, and the application prospect is wide. According to the present invention, the expression of the LXOL2 gene can be knocked down, the expression of pro-inflammatory factors TNF-alpha, IL-1beta and IL-6 can be significantly inhibited, the expression of anti-inflammatory factors TGF-beta can be promoted, and the gene can be used as the RA molecular targeting treatment tool;

The invention provides a use of a marker or a combination thereof in preparation of a product for prediction, diagnosis or auxiliary diagnosis of measurable residual diseases, the measurable residual diseases occur after clinical complete remission of acute myelogenous leukemia patients, and the marker or the combination thereof comprises a C-X-C chemokine receptor 4 gene. According to the method, a multi-parameter flow sorting technology is adopted, leukemia cell populations are separated from bone marrow samples of patients in the first diagnosis stage and the AML MRD stage, and a sufficient number of residual disease cells are successfully captured through a single cell transcriptome sequencing technology. The CXCR4 low-expression cell is identified to be capable of being used as a common marker of an MRD cell, and is verified in a clinical AML patient specimen. And an innovative scheme is provided for MRD monitoring of AML patients lacking clear molecular markers. And meanwhile, a CXCR4 low-expression cell is provided as a function substitution model of the MRD cell, so that the technical limitation of insufficient residual cells in the traditional research is broken through, and a reliable research system is established for systematically exploring the biological characteristics of the MRD cell.

The present invention relates to a nasal fluid sample obtained from a subject, the nasal fluid sample comprising one or more marker protein amyloid beta (A beta), phosphorylated Tau (pTau) and / or total Tau (tTau). The invention further relates to a nasal fluid sample comprising one or more marker proteins A [beta], pTau and / or tTau for use in a method for aiding in the diagnosis of a degenerative disease of the nervous system, and to the use of a nasal fluid sample comprising one or more marker proteins A [beta], pTau and / or tTau for aiding in the diagnosis of a degenerative disease of the nervous system. The invention further relates to a method for aiding the diagnosis of a nervous system degenerative disease in a subject / individual.

The invention discloses a heart failure biomarker and application thereof, relates to the technical field of biology, solves the technical problem that BNP is insufficient in early signal recognition of HFpEF, and is characterized by providing a biomarker LECT2 protein or LECT2 coding gene for diagnosis or auxiliary diagnosis of heart failure. The invention provides application of a product for quantitatively detecting LECT2 protein in preparation of a tool for diagnosing heart failure, the heart failure is ejection fraction retention type heart failure, a pharmaceutical composition for treating HFpEF is provided, the pharmaceutical composition comprises an LECT2 inhibitor, and the inhibitor is selected from one or more of shRNA of a targeted LECT2 gene, an antibody of the targeted LECT2 protein and an antagonist of a targeted LECT2 receptor; the effects of being beneficial to early recognition of high-risk patients and remarkably improving the accuracy of HFpEF diagnosis and the early detection capability are achieved.

Biomarkers that can support the diagnosis of inflammatory diseases and methods of their use. [Solution] A composition and method for detecting inflammasome components in a sample from a subject as a marker for inflammasome-related diseases or disorders such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammatory aging, or traumatic brain injury. Methods for using such inflammasome markers to determine prognosis, prescribe treatment, and monitor response to treatment in subjects with inflammasome-related diseases or disorders such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammatory aging, or traumatic brain injury are also described.

The application discloses application of a sugar chain marker combination in preparation of a product for diagnosing and predicting prognosis of pancreatic cancer, and the marker combination comprises the following N-glycan chains: NGA2F, NG1A2F-1, NG1A2F-2, NA2, NA2F, NA2FB, NA3 and NA3Fb. The application analyzes the correlation between the change of the sugar chain on the serum glycoprotein and the disease, establishes a prediction model of the sugar chain marker combination to detect the pancreatic cancer, thereby assisting in diagnosing and distinguishing the pancreatic cancer from non-pancreatic cancer, and meanwhile, the prognosis state of the pancreatic cancer patient treatment can be evaluated. The method for detecting the sugar chain marker combination has high sensitivity and high specificity for the pancreatic cancer, can help the pancreatic cancer patient to be found and treated early, and can predict and evaluate the prognosis state of the pancreatic cancer patient, thereby improving the overall cure rate and survival rate of the patient.

The application discloses a system and a kit for early auxiliary diagnosis of breast cancer and detection of micro residual lesions at various stages, and relates to the technical field of medical diagnosis.The system provided by the application uses the read value ratio of miRNA mature bodies and isomers to perform early auxiliary diagnosis of breast cancer and detection of micro residual lesions at various stages, and has high diagnostic sensitivity and specificity; and the system provides more accurate diagnostic basis for early adoption of treatment or intervention means by breast cancer patients.